PMID- 37550352
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20231118
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Aug 7
TI  - Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met 
      hereditary transthyretin amyloidosis.
PG  - 12755
LID - 10.1038/s41598-023-40029-4 [doi]
LID - 12755
AB  - This study reports the long-term results of trabeculectomy (LEC) for secondary 
      glaucoma in hereditary transthyretin (ATTRv) amyloidosis patients and its 
      correlation with prior vitrectomy. A retrospective case series was conducted 
      involving 31 consecutive eyes of 20 ATTRv amyloidosis patients who underwent LEC 
      between 2007 and 2020. The mean follow-up period was 73.2 +/- 37.0 months (range: 
      20-181 months). Postoperative intraocular pressures (IOPs) were evaluated based 
      on the following criteria: (a) IOP between 6 and 21 mmHg without additional 
      glaucoma surgeries, except for laser suture lysis, (b) IOP between 6 and 15 mmHg 
      without additional glaucoma surgeries, except for laser suture lysis, and (c) IOP 
      between 6 and 21 mmHg without additional glaucoma surgeries, except for needling 
      and laser suture lysis. Kaplan-Meier analysis revealed survival rates after LEC 
      of 0.52 at 36 months, 0.42 at 60 months, and 0.25 at 84 months under criterion 
      (a); 0.49 at 36 months, 0.27 at 60 months, and 0.11 at 84 months under criterion 
      (b); and 0.76 at 36 months, 0.71 at 60 months, and 0.65 at 84 months under 
      criterion (c). Eyes with a history of small gauge transconjunctival vitrectomy 
      (SGTV) exhibited a tendency towards lower survival rates, although no 
      statistically significant difference was observed (log-rank test; p = 0.193 under 
      criterion (a) and p = 0.0553 under criterion (b)). Our findings suggest that LEC 
      and additional needling procedures can provide some control over IOP; however, 
      the overall postoperative outcomes of LEC for ATTRv amyloidosis remain 
      unsatisfactory, even in the era of SGTV with reduced conjunctival scarring.
CI  - (c) 2023. Springer Nature Limited.
FAU - Kitahara, Junya
AU  - Kitahara J
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Kakihara, Shinji
AU  - Kakihara S
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan. kakihara@shinshu-u.ac.jp.
FAU - Mukawa, Shuji
AU  - Mukawa S
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Hirano, Takao
AU  - Hirano T
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Imai, Akira
AU  - Imai A
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Miyahara, Teruyoshi
AU  - Miyahara T
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Murata, Toshinori
AU  - Murata T
AD  - Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230807
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - Amyloidosis, Hereditary, Transthyretin-Related
SB  - IM
MH  - Humans
MH  - *Trabeculectomy/methods
MH  - Retrospective Studies
MH  - *Glaucoma/surgery
MH  - *Amyloid Neuropathies, Familial/complications/genetics/surgery
MH  - Intraocular Pressure
MH  - Treatment Outcome
MH  - Follow-Up Studies
PMC - PMC10406936
COIS- The authors declare no competing interests.
EDAT- 2023/08/08 00:42
MHDA- 2023/08/09 06:43
PMCR- 2023/08/07
CRDT- 2023/08/07 23:21
PHST- 2023/03/24 00:00 [received]
PHST- 2023/08/03 00:00 [accepted]
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/08/08 00:42 [pubmed]
PHST- 2023/08/07 23:21 [entrez]
PHST- 2023/08/07 00:00 [pmc-release]
AID - 10.1038/s41598-023-40029-4 [pii]
AID - 40029 [pii]
AID - 10.1038/s41598-023-40029-4 [doi]
PST - epublish
SO  - Sci Rep. 2023 Aug 7;13(1):12755. doi: 10.1038/s41598-023-40029-4.